Verona Pharma

135 articles with Verona Pharma

• Verona Pharma and Nuance Pharma Announce $219 Million Strategic Collaboration to Develop and Commercialize Ensifentrine in Greater China

  6/10/2021

  Verona Pharma plc and Nuance Pharma Limited, announce that the companies have entered into an agreement granting Nuance Pharma, a Shanghai-based specialty pharmaceutical company, the rights to develop and commercialize ensifentrine in Greater China.

• Verona Pharma to Present at Jefferies Virtual Healthcare Conference - May 25, 2021

  5/25/2021

  Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Chief Executive Officer and President, will present a company overview at the Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 9:00 AM ET.

• Verona Pharma to Present Expanded Analysis of Phase 2b COPD Data with Ensifentrine at the American Thoracic Society 2021 International Conference

  5/4/2021

  Posters highlight ensifentrine’s safety profile and its potential to improve lung function and quality of life irrespective of COPD severity

• Verona Pharma Reports First Quarter 2021 Financial Results and Provides Corporate Update

  4/29/2021

  Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its financial results for the three months ended March 31, 2021, and provides a corporate update.

• Verona Pharma Announces Publication of Phase 2b Dose-Ranging COPD Data in the International Journal of Chronic Obstructive Pulmonary DiseaseEnsifentrine improves lung function and quality of life when added to maintenance tiotropium

  4/27/2021

  Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces publication of efficacy and safety results from a previously reported Phase 2b clinical trial with nebulized ensifentrine added on to maintenance bronchodilator therapy in symptomatic chronic obstructive pulmonary disease patients.

• Verona Pharma Reports Results of Pilot Study of pMDI Ensifentrine in U.S. Patients Hospitalized with COVID-19

  4/23/2021

  Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces data from a pilot study of a pressurized metered-dose inhaler formulation of ensifentrine showed that ensifentrine was safe and well tolerated in patients infected with SARS-CoV-2, the virus that causes COVID-19.

• 

  Pfizer-BioNTech, Moderna Vaccines Effective Against Variants and More COVID-19 News

  4/23/2021

  With the U.S. Food and Drug Administration’s vaccines advisory committee meeting being held today to discuss the Johnson & Johnson vaccine and blood clotting, there’s even more interest in what’s going on in the pandemic than usual. Here’s a look at some of the top stories.

• Verona Pharma to Report First Quarter 2021 Financial Results and Provide Corporate Update

  4/21/2021

  Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the three months ended March 31, 2021 on Thursday, April 29, 2021 and host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m.

• Lisa Deschamps Joins Verona Pharma as Non-Executive Director

  3/2/2021

  Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces, effective March 1, 2021, Ms. Lisa Deschamps has joined the board as a Non-Executive Director.

• Verona Pharma to Present at H.C. Wainwright Global Life Sciences Virtual Conference

  3/1/2021

  Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Chief Executive Officer and President, will present a company overview at the H.C. Wainwright Global Life Sciences Conference.

• Verona Pharma Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

  2/25/2021

  Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its financial results for the fourth quarter and full year ended December 31, 2020, and provides a corporate update.

• Verona Pharma to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update

  2/18/2021

  Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the fourth quarter and full year ended December 31, 2020 on Thursday, February 25, 2021 and host an investment community conference call at 9:00 a.m. EST / 2:00 p.m. GMT to discuss these financial results and provide a corporate update.

• Verona Pharma Reports Positive Phase 2 Results with pMDI Formulation of Ensifentrine in COPD

  2/2/2021

  Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces positive Phase 2 data with a pressurized metered-dose inhaler formulation of ensifentrine in patients with moderate to severe chronic obstructive pulmonary disease.

• Verona Pharma Completes Enrollment in Pilot Study of pMDI Ensifentrine in U.S. Patients Hospitalized with COVID-19Top-line results expected in 2Q 2021

  1/14/2021

  Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces it has completed enrollment in its pilot clinical study evaluating the efficacy and safety of ensifentrine delivered via pressurized metered-dose inhaler formulation in U.S.

• Verona Pharma to Present at H.C. Wainwright Virtual BioConnect Conference - Jan 05, 2021

  1/5/2021

  Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Chief Executive Officer and President, will present a company overview at the H.C. Wainwright Virtual BioConnect Conference.

• Verona Pharma Announces November 2020 Virtual Investor Conference Participation

  11/9/2020

  Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Chief Executive Officer and President, will present a company overview at the following virtual investor conferences in November 2020:

• Verona Pharma plc Operational Update and Financial Results for the Three and Nine Months Ended September 30, 2020

  10/29/2020

  Verona Pharma plc, a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces financial results for the three and nine months ended September 30, 2020 and provides a corporate update.

• Verona Pharma to Announce Interim Results for the Three and Nine Months Ended September 30, 2020 and Provide Corporate Update

  10/22/2020

  Verona Pharma plc announces that it will report its unaudited financial results for the three and nine months ended September 30, 2020 on Thursday, October 29, 2020 and host an investment community conference call at 9:00 a.m. EDT / 1:00 p.m. GMT to discuss these financial results and provide a corporate update.

• Verona Pharma to Present Phase 2b COPD Symptom and Quality of Life Data with Ensifentrine at CHEST 2020Posters highlight ensifentrine’s potential to provide rapid benefits

  10/13/2020

  Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will present new analyses from a Phase 2b clinical trial with nebulized ensifentrine in chronic obstructive pulmonary disease at CHEST Annual Meeting 2020 taking place on October 18-21.

• Verona Pharma Initiates Pilot Study with pMDI Ensifentrine in U.S. Patients Hospitalized with COVID-19

  9/8/2020

  Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces the initiation of a pilot study to investigate the efficacy and safety of ensifentrine delivered via pressurized metered-dose inhaler formulation in U.S. patients hospitalized with COVID-19.